Revvity Beats Q3 Estimates on Strong Revenue

The Waltham, Massachusetts scientific instruments maker posted third-quarter results above analyst expectations.

Updated on Nov. 3, 2026 in Economic Indicators

Vector-style editorial illustration of stainless-steel pipette tips and a clear glass cylinder on a grey field beside a translucent blue sheet, evoking laboratory instruments. — Revvity posted third-quarter revenue of $728.9 million and adjusted earnings of $1.38 per share, both above Wall Street estimates, and raised its full-year outlook. AI Illustration. Upload story photo >

Revvity reported third-quarter profit of $62.3 million, or 56 cents per share, and revenue of $728.9 million. Adjusted earnings of $1.38 per share and adjusted revenue of $709.6 million both exceeded analyst estimates.

Why it matters

The results show the company outperforming Wall Street forecasts on both earnings and sales in the period. Its full-year outlook of $5.40 to $5.45 per share in earnings and $2.86 billion in revenue sets a benchmark for investors tracking the scientific instruments sector.

Revvity's third-quarter adjusted earnings of $1.38 per share beat the $1.29 analyst average, and adjusted revenue of $709.6 million topped the $707 million estimate. GAAP profit was $62.3 million, or 56 cents per share, and the company did not explain the difference between GAAP and adjusted figures in the reported results.

The players

Revvity

Revvity is a scientific instruments maker headquartered in Waltham, Massachusetts, serving life science and diagnostics markets.

Zacks

Zacks is an independent investment research firm that compiles analyst consensus estimates used as a benchmark for corporate earnings.

The details

Revvity reported third-quarter revenue of $728.9 million, which exceeded Wall Street expectations. The company expects full-year earnings of $5.40 to $5.45 per share and full-year revenue of $2.86 billion.

Revvity reported its third-quarter earnings on November 3, 2026.

Market Landscape

Revvity's results beat the Zacks analyst consensus on adjusted earnings and revenue for the quarter. The company's expected full-year revenue of $2.86 billion sets a forward benchmark against which future quarters will be measured by analysts tracking the scientific instruments market.

Investors tracking Revvity can compare the company's full-year guidance of $5.40 to $5.45 per share against its quarterly results when evaluating its stock. Shareholders should note that the GAAP profit of 56 cents per share is well below the $1.38 adjusted figure, a gap that affects how the quarter's performance is measured.

The takeaway

Revvity beat analyst expectations on both earnings and revenue this quarter, but investors should weigh the gap between GAAP and adjusted profit when judging the company's underlying results.